Strata Oncology

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.

The companies are using Strata's biomarker technology to identify genomic subpopulations of cancer patients who respond to Arcus' investigational immunotherapy drug.

The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.

Strata will refer individuals with HER-2 mutations identified through its screening trial for consideration as subjects in Puma's SUMMIT trial.

The company intends to use the funds to support submission of its NGS assay to the FDA, adoption of its testing by more health systems, and continued R&D.

Get the latest news in the Genetics and Genomics industries right here. For the week of Dec 15, 2017.

The company hopes to build enrollment of men with advanced prostate cancer within its larger Strata Trial — which provides free targeted sequencing and tracks its impact on clinical trial enrollment.

Strata will help Epizyme identify cancer patients for enrollment in a Phase II trial of its non-Hodgkins lymphoma drug tazemetostat.